Jefferies Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $40

Futu News15:31 · Ratings

Supernus Pharmaceuticals (NASDAQ:SUPN) Shareholders Have Earned a 9.4% CAGR Over the Last Five Years

Yahoo FinanceJan 7 19:08

Cantor Fitzgerald Initiates Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Announces Target Price $57

Futu NewsJan 6 19:34 · Ratings

Express News | Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (Viloxazine) in Canada

BreakingsDec 17, 2024 05:30

Knight Therapeutics Announces Filing of New Drug Submission for Qelbree (Viloxazine) in Canada

GlobeNewswireDec 17, 2024 05:30

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Simply Wall StDec 14, 2024 20:33